{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T18:06:04Z","timestamp":1776103564134,"version":"3.50.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2024,6,15]],"date-time":"2024-06-15T00:00:00Z","timestamp":1718409600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,6,15]],"date-time":"2024-06-15T00:00:00Z","timestamp":1718409600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2024,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Haploidentical stem cell transplantation (haplo-SCT) using post-transplantation cyclophosphamide (post-Cy) is considered a reasonable therapeutic option for patients who lack matched donor or who urgently need transplant procedure due to high risk disease. We analyzed the results of haplo-SCT performed in years 2018\u20132023. Eighty one patients (46 males) at median age of 52 years underwent haplo-SCT using peripheral blood as a stem cell source in most cases. Indications included hematological malignancies (acute leukemias in 88% of cases). In 25 cases (31%) transplantation was performed in relapsed\/refractory disease. Majority of patients (61%) presented with very high and high disease risk index (DRI). Conditioning regimens were as follows: nonmyeloablative \u2212\u200946 cases (57%), myeloablative \u2013 in 18 (22%) and reduced intensity \u2013 17(20%). 90% of patients engrafted. All patients received unified immunosuppressive treatment (post-Cy\/TAC\/MMF). Median follow-up time was 12 months The cumulative incidence of acute and chronic GVHD was 37.5% and 37.6%, respectively. Estimated 2-year overall survival (OS) was 43.1% and donor\u2019s age was the only factor influencing survival. The 2-year progression-free survival (PFS) was 42.5%, whereas relapse incidence (RI) \u2212\u200935%. The cumulative incidence of non-relapse mortality (NRM) was 44% and was mostly due to infections. Haplo-SCT is a feasible treatment option for hematological patients. Younger donor improves post-transplant survival. Strategies to reduce infection-related mortality and relapse rate remain a challenge.<\/jats:p>","DOI":"10.1007\/s00277-024-05848-z","type":"journal-article","created":{"date-parts":[[2024,6,15]],"date-time":"2024-06-15T05:02:02Z","timestamp":1718427722000},"page":"3095-3104","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Donor\u2019s age influences outcome in haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide - a single center experience"],"prefix":"10.1007","volume":"103","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5215-5264","authenticated-orcid":false,"given":"Patrycja","family":"Zieli\u0144ska","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agata","family":"Wieczorkiewicz-Kabut","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krzysztof","family":"Bia\u0142as","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Kocl\u0119ga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karolina","family":"Gruenpeter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Kopi\u0144ska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krzysztof","family":"Wo\u017aniczka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Izabela","family":"Noster","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomasz","family":"Gromek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaros\u0142aw","family":"Czy\u017c","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebastian","family":"Grosicki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agnieszka","family":"Wierzbowska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacek","family":"Krzanowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aleksandra","family":"Butrym","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grzegorz","family":"Helbig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,6,15]]},"reference":[{"key":"5848_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/JGO.18.00130","volume":"4","author":"MA Khan","year":"2018","unstructured":"Khan MA, Bashir Q, Chaudhry QU, Ahmed P, Satti TM, Mahmood SK (2018) Review of Haploidentical hematopoietic cell transplantation. J Glob Oncol 4:1\u201313. https:\/\/doi.org\/10.1200\/JGO.18.00130","journal-title":"J Glob Oncol"},{"issue":"3","key":"5848_CR2","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1007\/s00277-021-04731-5","volume":"101","author":"K Harada","year":"2022","unstructured":"Harada K, Mizuno S, Yano S, Takami A, Ishii H, Ikegame K, Najima Y, Kako S, Ashida T, Shiratori S, Ota S, Onizuka M, Fukushima K, Fukuda T, Ichinohe T, Atsuta Y, Yanada M (2022) Donor lymphocyte infusion after haploidentical hematopoietic stem cell transplantation for acute myeloid leukemia. Ann Hematol 101(3):643\u2013653. https:\/\/doi.org\/10.1007\/s00277-021-04731-5","journal-title":"Ann Hematol"},{"issue":"7","key":"5848_CR3","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1038\/s41409-023-01980-y","volume":"58","author":"A Nagler","year":"2023","unstructured":"Nagler A, Labopin M, Mielke S, Passweg J, Blaise D, Gedde-Dahl T, Cornelissen JJ, Salmenniemi U, Yakoub-Agha I, Rem\u00e9nyi P, Soci\u00e9 G, van Gorkom G, Labussi\u00e8re-Wallet H, Huang XJ, Rubio MT, Byrne J, Craddock C, Gri\u0161kevi\u010dius L, Ciceri F, Mohty M (2023) Matched related versus unrelated versus haploidentical donors for allogeneic transplantation in AML patients achieving first complete remission after two induction courses: a study from the ALWP\/EBMT. Bone Marrow Transpl 58(7):791\u2013800. https:\/\/doi.org\/10.1038\/s41409-023-01980-y","journal-title":"Bone Marrow Transpl"},{"issue":"1","key":"5848_CR4","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s13045-020-00882-6","volume":"6","author":"J Sanz","year":"2020","unstructured":"Sanz J, Galimard JE, Labopin M, Afanasyev B, Angelucci E, Ciceri F, Blaise D, Cornelissen JJ, Meijer E, Diez-Martin JL, Koc Y, Rovira M, Castagna L, Savani B, Ruggeri A, Nagler A, Mohty M, Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT) (2020) Post-transplant cyclophosphamide after matched sibling, unrelated and haploidentical donor transplants in patients with acute myeloid leukemia: a comparative study of the ALWP EBMT. J Hematol Oncol 6(1):46. https:\/\/doi.org\/10.1186\/s13045-020-00882-6","journal-title":"J Hematol Oncol"},{"issue":"3","key":"5848_CR5","doi-asserted-by":"publisher","first-page":"524","DOI":"10.3324\/haematol.2017.187450","volume":"104","author":"E Brissot","year":"2019","unstructured":"Brissot E, Labopin M, Ehninger G, Stelljes M, Brecht A, Ganser A, Tischer J, Kr\u00f6ger N, Afanasyev B, Finke J, Elmaagacli A, Einsele H, Mohty M, Nagler A (2019) Haploidentical versus unrelated allogeneic stem cell transplantation for relapsed\/refractory acute myeloid leukemia: a report on 1578 patients from the Acute Leukemia Working Party of the EBMT. Haematologica 104(3):524\u2013532. https:\/\/doi.org\/10.3324\/haematol.2017.187450","journal-title":"Haematologica"},{"issue":"12","key":"5848_CR6","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.1182\/bloodadvances.2019000050","volume":"253","author":"A Rashidi","year":"2019","unstructured":"Rashidi A, Hamadani M, Zhang MJ, Wang HL, Abdel-Azim H, Aljurf M, Assal A, Bajel A, Bashey A, Battiwalla M, Beitinjaneh AM, Bejanyan N, Bhatt VR, Bola\u00f1os-Meade J, Byrne M, Cahn JY, Cairo M, Ciurea S, Copelan E, Cutler C, Daly A, Diaz MA, Farhadfar N, Gale RP, Ganguly S, Grunwald MR, Hahn T, Hashmi S, Hildebrandt GC, Holland HK, Hossain N, Kanakry CG, Kharfan-Dabaja MA, Khera N, Koc Y, Lazarus HM, Lee JW, Maertens J, Martino R, McGuirk J, Munker R, Murthy HS, Nakamura R, Nathan S, Nishihori T, Palmisiano N, Patel S, Pidala J, Olin R, Olsson RF, Oran B, Ringden O, Rizzieri D, Rowe J, Savoie ML, Schultz KR, Seo S, Shaffer BC, Singh A, Solh M, Stockerl-Goldstein K, Verdonck LF, Wagner J, Waller EK, De Lima M, Sandmaier BM, Litzow M, Weisdorf D, Romee R, Saber W (2019) Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission. Blood Adv 253(12):1826\u20131836. https:\/\/doi.org\/10.1182\/bloodadvances.2019000050","journal-title":"Blood Adv"},{"issue":"1","key":"5848_CR7","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s13045-021-01065-7","volume":"14","author":"A Nagler","year":"2021","unstructured":"Nagler A, Labopin M, Houhou M, Aljurf M, Mousavi A, Hamladji RM, Al Zahrani M, Bondarenko S, Arat M, Angelucci E, Koc Y, G\u00fclbas Z, Sica S, Bourhis JH, Canaani J, Brissot E, Giebel S, Mohty M (2021) Outcome of haploidentical versus matched sibling donors in hematopoietic stem cell transplantation for adult patients with acute lymphoblastic leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and marrow transplantation. J Hematol Oncol 14(1):53. https:\/\/doi.org\/10.1186\/s13045-021-01065-7","journal-title":"J Hematol Oncol"},{"key":"5848_CR8","doi-asserted-by":"publisher","unstructured":"Wang Y, Chang YJ, Xu LP, Liu KY, Liu DH, Zhang XH, Chen H, Han W, Chen YH, Wang FR, Wang JZ, Chen Y, Yan CH, Huo MR, Li D, Huang XJ (2014) Who is the best donor for a related HLA haplotype-mismatched transplant? Blood 7;124(6):843\u2009\u2013\u200950. https:\/\/doi.org\/10.1182\/blood-2014-03-563130","DOI":"10.1182\/blood-2014-03-563130"},{"issue":"6","key":"5848_CR9","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/j.bbmt.2008.03.005","volume":"14","author":"L Luznik","year":"2008","unstructured":"Luznik L, O\u2019Donnell PV, Symons HJ, Chen AR, Leffell MS, Zahurak M, Gooley TA, Piantadosi S, Kaup M, Ambinder RF, Huff CA, Matsui W, Bola\u00f1os-Meade J, Borrello I, Powell JD, Harrington E, Warnock S, Flowers M, Brodsky RA, Sandmaier BM, Storb RF, Jones RJ, Fuchs EJ (2008) HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transpl 14(6):641\u2013650. https:\/\/doi.org\/10.1016\/j.bbmt.2008.03.005","journal-title":"Biol Blood Marrow Transpl"},{"key":"5848_CR10","doi-asserted-by":"publisher","unstructured":"Luznik L, Jalla S, Engstrom LW, Iannone R, Fuchs EJ (2001) Durable engraftment of major histocompatibility complex-incompatible cells after nonmyeloablative conditioning with fludarabine, low-dose total body irradiation, and posttransplantation cyclophosphamide. Blood 1;98(12):3456-64. https:\/\/doi.org\/10.1182\/blood.v98.12.3456","DOI":"10.1182\/blood.v98.12.3456"},{"key":"5848_CR11","doi-asserted-by":"publisher","unstructured":"Armand P, Kim HT, Logan BR, Wang Z, Alyea EP, Kalaycio ME, Maziarz RT, Antin JH, Soiffer RJ, Weisdorf DJ, Rizzo JD, Horowitz MM, Saber W (2014) Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation. Blood 5;123(23):3664-71. https:\/\/doi.org\/10.1182\/blood-2014-01-552984","DOI":"10.1182\/blood-2014-01-552984"},{"issue":"5","key":"5848_CR12","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1038\/s41409-017-0062-8","volume":"53","author":"SO Ciurea","year":"2018","unstructured":"Ciurea SO, Cao K, Fernandez-Vina M, Kongtim P, Malki MA, Fuchs E, Luznik L, Huang XJ, Ciceri F, Locatelli F, Aversa F, Castagna L, Bacigalupo A, Martelli M, Blaise D, Handgretinger R, Roy DC, O\u2019Donnell P, Bashey A, Lazarus HM, Ballen K, Savani BN, Mohty M, Nagler A (2018) The European Society for Blood and Marrow Transplantation (EBMT) Consensus guidelines for the detection and treatment of Donor-specific Anti-HLA antibodies (DSA) in Haploidentical hematopoietic cell transplantation. Bone Marrow Transpl 53(5):521\u2013534. https:\/\/doi.org\/10.1038\/s41409-017-0062-8","journal-title":"Bone Marrow Transpl"},{"issue":"8","key":"5848_CR13","doi-asserted-by":"publisher","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","volume":"15","author":"ML Sorror","year":"2005","unstructured":"Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG, Storer B (2005) Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic. HCT Blood 15(8):2912\u20132919. https:\/\/doi.org\/10.1182\/blood-2005-05-2004","journal-title":"HCT Blood"},{"key":"5848_CR14","volume-title":"The EBMT Handbook: hematopoietic stem cell transplantation and Cellular therapies [Internet]","year":"2019","unstructured":"Carreras E, Dufour C, Mohty M, Kr\u00f6ger N (eds) (2019) The EBMT Handbook: hematopoietic stem cell transplantation and Cellular therapies [Internet], 7th edn. Springer, Cham (CH)","edition":"7"},{"key":"5848_CR15","doi-asserted-by":"publisher","unstructured":"Anasetti C, Amos D, Beatty PG, Appelbaum FR, Bensinger W, Buckner CD, Clift R, Doney K, Martin PJ, Mickelson E et al (989) Effect of HLA compatibility on engraftment of bone marrow transplants in patients with leukemia or lymphoma. N Engl J Med 26;320(4):197\u2013204. https:\/\/doi.org\/10.1056\/NEJM198901263200401","DOI":"10.1056\/NEJM198901263200401"},{"issue":"1","key":"5848_CR16","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.bbmt.2017.10.002","volume":"24","author":"AM Raiola","year":"2018","unstructured":"Raiola AM, Risitano A, Sacchi N, Giannoni L, Signori A, Aquino S, Bregante S, Di Grazia C, Dominietto A, Geroldi S, Ghiso A, Gualandi F, Lamparelli T, Tedone E, Van Lint MT, Varaldo R, Ibatici A, Marani C, Marotta S, Guolo F, Avenoso D, Garbarino L, Pane F, Bacigalupo A, Angelucci E (2018) Impact of HLA Disparity in Haploidentical Bone Marrow Transplantation followed by high-dose cyclophosphamide. Biol Blood Marrow Transpl 24(1):119\u2013126. https:\/\/doi.org\/10.1016\/j.bbmt.2017.10.002","journal-title":"Biol Blood Marrow Transpl"},{"issue":"5","key":"5848_CR17","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1038\/s41409-017-0072-6","volume":"53","author":"MR Huo","year":"2018","unstructured":"Huo MR, Pei XY, Li D, Chang YJ, Xu LP, Zhang XH, Liu KY, Huang XJ (2018) Impact of HLA allele mismatch at HLA-A, -B, -C, -DRB1, and -DQB1 on outcomes in haploidentical stem cell transplantation. Bone Marrow Transpl 53(5):600\u2013608. https:\/\/doi.org\/10.1038\/s41409-017-0072-6","journal-title":"Bone Marrow Transpl"},{"issue":"4","key":"5848_CR18","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1016\/j.bbmt.2009.11.011","volume":"16","author":"YL Kasamon","year":"2010","unstructured":"Kasamon YL, Luznik L, Leffell MS, Kowalski J, Tsai HL, Bola\u00f1os-Meade J, Morris LE, Crilley PA, O\u2019Donnell PV, Rossiter N, Huff CA, Brodsky RA, Matsui WH, Swinnen LJ, Borrello I, Powell JD, Ambinder RF, Jones RJ, Fuchs EJ (2010) Nonmyeloablative HLA-haploidentical bone marrow transplantation with high-dose posttransplantation cyclophosphamide: effect of HLA disparity on outcome. Biol Blood Marrow Transpl 16(4):482\u2013489. https:\/\/doi.org\/10.1016\/j.bbmt.2009.11.011","journal-title":"Biol Blood Marrow Transpl"},{"issue":"1","key":"5848_CR19","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s13045-023-01421-9","volume":"18","author":"Y Ye","year":"2023","unstructured":"Ye Y, Labopin M, Chen J, Gulbas Z, Zhang X, Koc Y, Blaise D, Ciceri F, Polge E, Houhou M, Li L, Luo Y, Wu D, Huang H, Mohty M, Gorin NC (2023) Similar outcomes following non-first-degree and first-degree related donor haploidentical hematopoietic cell transplantation for acute leukemia patients in complete remission: a study from the Global Committee and the Acute Leukemia Working Party of the European Society for Blood and marrow transplantation. J Hematol Oncol 18(1):25. https:\/\/doi.org\/10.1186\/s13045-023-01421-9","journal-title":"J Hematol Oncol"},{"issue":"7","key":"5848_CR20","doi-asserted-by":"publisher","first-page":"e920","DOI":"10.1097\/HS9.0000000000000920","volume":"27","author":"MA Kharfan-Dabaja","year":"2023","unstructured":"Kharfan-Dabaja MA, Labopin M, Ayala E, Bazarbachi A, Blaise D, Vydra J, Bramanti S, It\u00e4l\u00e4-Remes M, Schmid C, Busca A, Forcade E, Rabitsch W, Zecca M, Kr\u00f6ger N, Bulabois CE, Grillo G, Rambaldi A, Fanin R, Zallio F, Di Renzo N, Koc Y, Novis Y, McDonald A, Herrera Arroyo C, Sanz J, Nagler A, Ciceri F, Mohty M (2023) Significance of degree of HLA disparity using T-cell replete peripheral blood stem cells from Haploidentical Donors with Posttransplantation Cyclophosphamide in AML in First Complete Hematologic Remission: a study of the Acute Leukemia Working Party of the EBMT. Hemasphere 27(7):e920. https:\/\/doi.org\/10.1097\/HS9.0000000000000920","journal-title":"Hemasphere"},{"issue":"1","key":"5848_CR21","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1007\/s12185-019-02660-8","volume":"110","author":"J Sugita","year":"2019","unstructured":"Sugita J (2019) HLA-haploidentical stem cell transplantation using posttransplant cyclophosphamide. Int J Hematol 110(1):30\u201338. https:\/\/doi.org\/10.1007\/s12185-019-02660-8","journal-title":"Int J Hematol"},{"issue":"1","key":"5848_CR22","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s13045-018-0564-x","volume":"2","author":"L Xu","year":"2018","unstructured":"Xu L, Chen H, Chen J, Han M, Huang H, Lai Y, Liu D, Liu Q, Liu T, Jiang M, Ren H, Song Y, Sun Z, Wang J, Wu D, Zhou D, Zou P, Liu K, Huang X (2018) The consensus on indications, conditioning regimen, and donor selection of allogeneic hematopoietic cell transplantation for hematological diseases in China-recommendations from the Chinese Society of Hematology. J Hematol Oncol 2(1):33. https:\/\/doi.org\/10.1186\/s13045-018-0564-x","journal-title":"J Hematol Oncol"},{"issue":"3","key":"5848_CR23","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1182\/bloodadvances.2017014829","volume":"13","author":"SR McCurdy","year":"2018","unstructured":"McCurdy SR, Zhang MJ, St Martin A, Al Malki MM, Bashey A, Gaballa S, Keesler DA, Hamadani M, Norkin M, Perales MA, Reshef R, Rocha V, Romee R, Solh M, Urbano-Ispizua A, Waller EK, Fuchs EJ, Eapen M (2018) Effect of donor characteristics on haploidentical transplantation with posttransplantation cyclophosphamide. Blood Adv 13(3):299\u2013307. https:\/\/doi.org\/10.1182\/bloodadvances.2017014829","journal-title":"Blood Adv"},{"key":"5848_CR24","doi-asserted-by":"publisher","unstructured":"Stern M, Ruggeri L, Mancusi A, Bernardo ME, de Angelis C, Bucher C, Locatelli F, Aversa F, Velardi A (2008) Survival after T cell-depleted haploidentical stem cell transplantation is improved using the mother as donor. Blood 1;112(7):2990-5. https:\/\/doi.org\/10.1182\/blood-2008-01-135285","DOI":"10.1182\/blood-2008-01-135285"},{"issue":"2","key":"5848_CR25","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1002\/ajh.24963","volume":"93","author":"J Canaani","year":"2018","unstructured":"Canaani J, Savani BN, Labopin M, Huang XJ, Ciceri F, Arcese W, Koc Y, Tischer J, Blaise D, G\u00fclbas Z, Van Lint MT, Bruno B, Mohty M, Nagler A (2018) Donor age determines outcome in acute leukemia patients over 40 undergoing haploidentical hematopoietic cell transplantation. Am J Hematol 93(2):246\u2013253. https:\/\/doi.org\/10.1002\/ajh.24963","journal-title":"Am J Hematol"},{"issue":"3","key":"5848_CR26","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1053\/j.seminhematol.2018.08.003","volume":"56","author":"P Kongtim","year":"2019","unstructured":"Kongtim P, Ciurea SO (2019) Who is the best donor for haploidentical stem cell transplantation? Semin Hematol 56(3):194\u2013200. https:\/\/doi.org\/10.1053\/j.seminhematol.2018.08.003","journal-title":"Semin Hematol"},{"issue":"19","key":"5848_CR27","doi-asserted-by":"publisher","first-page":"3024","DOI":"10.1182\/blood-2015-01-623991","volume":"7","author":"SR McCurdy","year":"2015","unstructured":"McCurdy SR, Kanakry JA, Showel MM, Tsai HL, Bola\u00f1os-Meade J, Rosner GL, Kanakry CG, Perica K, Symons HJ, Brodsky RA, Gladstone DE, Huff CA, Pratz KW, Prince GT, Dezern AE, Gojo I, Matsui WH, Borrello I, McDevitt MA, Swinnen LJ, Smith BD, Levis MJ, Ambinder RF, Luznik L, Jones RJ, Fuchs EJ, Kasamon YL (2015) Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide. Blood 7(19):3024\u20133031. https:\/\/doi.org\/10.1182\/blood-2015-01-623991","journal-title":"Blood"},{"issue":"5","key":"5848_CR28","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/j.bbmt.2017.02.009","volume":"23","author":"S Damodar","year":"2017","unstructured":"Damodar S, Shanley R, MacMillan M, Ustun C, Weisdorf D (2017) Donor-to-recipient ABO mismatch does not impact outcomes of allogeneic hematopoietic cell transplantation regardless of Graft source. Biol Blood Marrow Transpl 23(5):795\u2013804. https:\/\/doi.org\/10.1016\/j.bbmt.2017.02.009","journal-title":"Biol Blood Marrow Transpl"},{"issue":"6","key":"5848_CR29","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.3324\/haematol.2016.160804","volume":"102","author":"J Canaani","year":"2017","unstructured":"Canaani J, Savani BN, Labopin M, Huang XJ, Ciceri F, Arcese W, Tischer J, Koc Y, Bruno B, G\u00fclbas Z, Blaise D, Maertens J, Ehninger G, Mohty M, Nagler A (2017) Impact of ABO incompatibility on patients\u2019 outcome after haploidentical hematopoietic stem cell transplantation for acute myeloid leukemia - a report from the Acute Leukemia Working Party of the EBMT. Haematologica 102(6):1066\u20131074. https:\/\/doi.org\/10.3324\/haematol.2016.160804","journal-title":"Haematologica"},{"issue":"23","key":"5848_CR30","doi-asserted-by":"publisher","first-page":"3291","DOI":"10.1182\/blood.2020009362","volume":"10","author":"SR Goldsmith","year":"2021","unstructured":"Goldsmith SR, Abid MB, Auletta JJ, Bashey A, Beitinjaneh A, Castillo P, Chemaly RF, Chen M, Ciurea S, Dandoy CE, D\u00edaz M\u00c1, Fuchs E, Ganguly S, Kanakry CG, Kanakry JA, Kim S, Komanduri KV, Krem MM, Lazarus HM, Liu H, Ljungman P, Masiarz R, Mulroney C, Nathan S, Nishihori T, Page KM, Perales MA, Taplitz R, Romee R, Riches M (2021) Posttransplant cyclophosphamide is associated with increased cytomegalovirus infection: a CIBMTR analysis. Blood 10(23):3291\u20133305. https:\/\/doi.org\/10.1182\/blood.2020009362","journal-title":"Blood"},{"issue":"8","key":"5848_CR31","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1093\/cid\/ciz490","volume":"10","author":"P Ljungman","year":"2020","unstructured":"Ljungman P, Schmitt M, Marty FM, Maertens J, Chemaly RF, Kartsonis NA, Butterton JR, Wan H, Teal VL, Sarratt K, Murata Y, Leavitt RY, Badshah C (2020) A mortality analysis of Letermovir Prophylaxis for Cytomegalovirus (CMV) in CMV-seropositive recipients of allogeneic hematopoietic cell transplantation. Clin Infect Dis 10(8):1525\u20131533. https:\/\/doi.org\/10.1093\/cid\/ciz490","journal-title":"Clin Infect Dis"},{"key":"5848_CR32","doi-asserted-by":"publisher","first-page":"101092","DOI":"10.1016\/j.blre.2023.101092","volume":"62","author":"M Mikulska","year":"2023","unstructured":"Mikulska M, Bartalucci C, Raiola AM, Oltolini C (2023) Does PTCY increase the risk of infections? Blood Rev 62:101092. https:\/\/doi.org\/10.1016\/j.blre.2023.101092","journal-title":"Blood Rev"},{"issue":"10","key":"5848_CR33","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1038\/s41409-019-0475-7","volume":"54","author":"A Fayard","year":"2019","unstructured":"Fayard A, Daguenet E, Blaise D, Chevallier P, Labussi\u00e8re H, Berceanu A, Yakoub-Agha I, Soci\u00e9 G, Charbonnier A, Suarez F, Huynh A, Mercier M, Bulabois CE, Lioure B, Chantepie S, Beguin Y, Bourhis JH, Malfuson JV, Cl\u00e9ment L, de la Peffault R, Cornillon J (2019) Evaluation of infectious complications after haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide following reduced-intensity and myeloablative conditioning: a study on behalf of the Francophone Society of Stem Cell Transplantation and Cellular Therapy (SFGM-TC). Bone Marrow Transpl 54(10):1586\u20131594. https:\/\/doi.org\/10.1038\/s41409-019-0475-7","journal-title":"Bone Marrow Transpl"},{"issue":"10","key":"5848_CR34","doi-asserted-by":"publisher","first-page":"2432","DOI":"10.1038\/s41409-021-01328-4","volume":"56","author":"A Esquirol","year":"2021","unstructured":"Esquirol A, Pascual MJ, Kwon M, P\u00e9rez A, Parody R, Ferra C, Garcia Cadenas I, Herruzo B, Dorado N, Hernani R, Sanchez-Ortega I, Torrent A, Sierra J, Martino R, Spanish Group for Hematopoietic Stem cell Transplantation (GETH) (2021) Severe infections and infection-related mortality in a large series of haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide. Bone Marrow Transpl 56(10):2432\u20132444. https:\/\/doi.org\/10.1038\/s41409-021-01328-4","journal-title":"Bone Marrow Transpl"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05848-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-024-05848-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05848-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,27]],"date-time":"2024-07-27T06:09:33Z","timestamp":1722060573000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-024-05848-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,15]]},"references-count":34,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["5848"],"URL":"https:\/\/doi.org\/10.1007\/s00277-024-05848-z","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,15]]},"assertion":[{"value":"27 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This is a retrospective study and the consent of Ethics Committee was not required. Haploidentical stem cell transplantation remains a standard of care for hematological patients as per EBMT recommendations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written informed consent was obtained from all patients and is available per request.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"None.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}